Historical record - last NADAC effective date: 11/22/2023
Product Information
ESCITALOPRAM 20 MG TABLET is a generic product labeled by Jubilant Cadista Pharmaceuticals Inc., priced at $0.0816 per EA under NDC 59746028101. Its NADAC has been published 521 times since Dec 11, 2013.
FDA first approved this application on Sep 12, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 mg/1
Manufacturer
Jubilant Cadista Pharmaceuticals Inc.NDC
59746028101
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
11/22/2023
Active Ingredients
ESCITALOPRAM OXALATEApproval Type
Generic (ANDA)
FDA Application
ANDA202280FDA Approved
9/12/2012
TE Code
AB
On Market Since
1/1/2024
Pharmacological Classes
Price Statistics
The NADAC for ESCITALOPRAM 20 MG TABLET has been published 521 times since Dec 11, 2013, and over the history we have for it it has declined 45.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0816 per EA |
|---|---|
| All-time high | $0.1977 (Aug 12, 2015) |
| All-time low | $0.0716 (Jan 18, 2023) |
| Median price | $0.0888 |
| Average price | $0.1046 |
| Largest weekly change | -35.1% (Aug 19, 2015) |
| Weeks tracked | 521 |
| Tracking since | Dec 11, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-3.2%
5Y
-7.5%
All
-45.3%
Last surveyed Nov 29, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Jubilant Cadista Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Escitalopram Oxalate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ESCITALOPRAM 20 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ESCITALOPRAM 20 MG TABLET, manufactured by Jubilant Cadista Pharmaceuticals Inc., is $0.0816 per EA (NDC 59746028101), effective Nov 29, 2023.
How has the price of ESCITALOPRAM 20 MG TABLET changed over time?
Over the history we have for it, the NADAC for ESCITALOPRAM 20 MG TABLET has declined 45.3%. It has been tracked across 521 weekly CMS publications since Dec 11, 2013.
What are the highest and lowest recorded NADAC prices for ESCITALOPRAM 20 MG TABLET?
Since Dec 11, 2013, the NADAC for ESCITALOPRAM 20 MG TABLET has ranged from a low of $0.0716 (Jan 18, 2023) to a high of $0.1977 (Aug 12, 2015), with a median of $0.0888 per EA.
Are there cheaper alternatives to ESCITALOPRAM 20 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ESCITALOPRAM 20 MG TABLET, is $0.0631 per EA — about 23% below ESCITALOPRAM 20 MG TABLET.
Who manufactures ESCITALOPRAM 20 MG TABLET?
ESCITALOPRAM 20 MG TABLET (NDC 59746028101) is labeled by Jubilant Cadista Pharmaceuticals Inc., and CMS classifies it as a generic product.